548 filings
Page 7 of 28
8-K
3phesp
25 Apr 18
Other Events
12:00am
8-K
wmgjy0 7roppx9blit6
4 Apr 18
Abiomed Announces European Approval (CE Marking) for Impella 5.5™ and First Patient Treated at University Heart Center Hamburg
12:00am
8-K
4ylxets1m0rq78mnj3w
2 Apr 18
Abiomed to Appoint New Chief Financial Officer Todd A. Trapp
12:00am
8-K
31s pdmc3xo3v
8 Mar 18
Other Events
12:00am
8-K
11mi91u4j0g4t701
14 Feb 18
Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock
12:00am
8-K
7ceoq5byyzr gu084e
14 Feb 18
Abiomed Receives Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention (PCI) Procedures
12:00am
8-K
6fvf82cw314tfo7bjmi
1 Feb 18
Abiomed Announces Q3 Fy 2018 Record Revenue of $154 Million, Up 34% Over Prior Year
12:00am
8-K
296lh9josj
8 Jan 18
Abiomed Announces Preliminary Q3 Fy 2018 Revenue of $154 Million, Up 34% Over Prior Year
12:00am
8-K
u81 p0a239ttki64
26 Oct 17
Results of Operations and Financial Condition
12:00am
8-K
0o7y04yf3th7a
21 Sep 17
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure
12:00am
8-K
gihh8fiq7b5ebwh6r2j
12 Sep 17
Entry into a Material Definitive Agreement
12:00am
8-K
9auysd p9
28 Aug 17
Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former
12:00am
8-K
b6epv ecr
15 Aug 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
3o7ogkw0 r2mx
3 Aug 17
Other Events
12:00am
8-K
sxpmmu7uzkx40rr
27 Jul 17
Abiomed Announces Q1 Fy 2018 Revenue of $132.5 Million, Up 29% Over Prior Year
12:00am
DEFA14A
3nqxc
23 Jun 17
Additional proxy soliciting materials
12:00am